(Q28068166)

English

Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review

scientific article

In more languages

Statements

scholarly article

1 reference

1 reference

Europe PubMed Central

Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review (English)

1 reference

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

author name string

S. L. Hutchison

1

1 reference

J. K. Ghuman

2

1 reference

H. S. Ghuman

3

1 reference

I. Karpov

4

1 reference

J. M. Schuster

5

1 reference

language of work or name

1 reference

publication date

October 2016

1 reference

Therapeutic advances in psychopharmacology

1 reference

6

1 reference

5

1 reference

317-334

1 reference

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

Comparing the efficacy of medications for ADHD using meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

20 March 2017

The assessment of anxiety states by rating

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

7 April 2017

A rating scale for mania: reliability, validity and sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

7 April 2017

Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Oppositional defiant disorder dimensions and subtypes among detained male adolescent offenders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Prevalence and incidence of attention-deficit/hyperactivity disorder in Slovenian children and adolescents: a database study from a national perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish r

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

ADHD in children, adolescents, and adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Attention deficit hyperactivity disorder: the childhood co-morbidity that most influences the disability burden in Tourette syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Facilitation in recognizing pairs of words: Evidence of a dependence between retrieval operations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

The Overt Aggression Scale for the objective rating of verbal and physical aggression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

29 September 2017

Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Co-existing psychiatric problems in ADHD in the ADORE cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

2 June 2018

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

The efficacy of atomoxetine as adjunctive treatment for co-morbid substance use disorders and externalizing symptoms.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Refinement of the Children's Social Behavior Questionnaire (CSBQ): an instrument that describes the diverse problems seen in milder forms of PDD.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Affective valence and arousal in ADHD and normal boys during a startle habituation experiment.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Validation of the adult ADHD investigator symptom rating scale (AISRS).

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1177%2F2045125316647686

21 January 2018

Validity of the sluggish cognitive tempo symptom dimension in children: sluggish cognitive tempo and ADHD-inattention as distinct symptom dimensions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

27 November 2018

Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children --- United States, 2003 and 2007.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036135

27 November 2018

The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/27721971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Earlier onset of bipolar disorder in children by antidepressants or stimulants? An hypothesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27721971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine-induced life-threatening long QT syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/27721971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/2045125316647686

1 reference

1 reference

1 reference

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28068166&oldid=2126770528"